After Phase II miss, Gossamer aims to fail fast and succeed soon

26 April 2022

Reporting its second mid-stage flop in as many years, executives at Gossamer Bio (Nasdaq: GOSS) have vowed to quickly shift the focus onto more promising pipeline assets.

The San Diegan company, which is focused on developing candidates in immunology, inflammation and oncology, released data from the now-shuttered Phase II SHIFT-UC study on Monday.

The trial, which has been testing the oral prolyl hydroxylase inhibitor GB004 in mild-to-moderate active ulcerative colitis (UC), missed both primary and secondary endpoints.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK